Understanding the fiscal impact of expanding Medicaid coverage of continuous glucose monitors (CGMs) is a critical to the development of new legislation and changes in Medicaid policy. The resources in this section can help states in projecting the short- and long-term costs and return on investment for increasing Medicaid coverage of CGMs.
Personal Continuous Glucose Monitoring Use Among Adults with Type 2 Diabetes: Clinical Efficacy and Economic Impacts
Reviews research on clinical efficacy and economic data on the cost-effectiveness of CGM use.
Budget Impact of the Flash Continuous Glucose Monitoring System in Medicaid Diabetes Beneficiaries Treated with Intensive Insulin Therapy
Analyzes the positive economic impact of CGM use among individuals covered by Medicaid with diabetes treated with intensive insulin therapy.
Medical Expenditures Associated With Diabetes Among Youth With Medicaid Coverage
Estimates diabetes-related medical expenditures among patients under the age of 20 enrolled in Medicaid and includes estimates for enrollees who are Medicaid-eligible due to socio-economic and disability status.
Budget Impact Analysis Comparing Real-Time Continuous Glucose Monitoring with Self-Monitoring of Blood Glucose for all U.S. Medicaid Enrollees with Type 1 Diabetes
Describes calculated savings due to CGM use vs. blood glucose self-monitoring among people enrolled in Medicaid with type 1 diabetes.
Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial
Evaluates the societal cost-effectiveness of CGM use among patients with type 1 diabetes using multiple insulin injections.
